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Background: The hedgehog (Hh) signaling pathway is aberrantly activated in various cancers. Expression of the GLI
family of genes, which encode for transcriptional factors of the Hh pathway, has not been fully assessed in clinical
samples of advanced lung adenocarcinoma. In this study, we retrospectively evaluated the expression of the GLI
family of genes in advanced stage lung adenocarcinoma samples and determined their relation to patient survival.
Methods: The levels of GLI1, GLI2, and GLI3 mRNA expression were measured by quantitative real-time polymerase
chain reaction in surgically obtained tissue samples from stage II-IV lung adenocarcinoma patients (n = 102). Pairwise
comparisons between all three GLI mRNA expression were performed, and after dichotomizing the patients into low
and high expression groups according to each GLI mRNA expression level, survival curves were calculated and
multivariate analyses were conducted.
Results: Significant positive correlation was found between GLI1 and GLI3 mRNA expression (P <0.001). Tumors with
higher expression (upper 15%) of GLI1 or GLI3 mRNA were associated with poor survival in stage II-IV (5-year overall
survival rates: GLI1 mRNA low, 41.7% vs. high, 20.0%, P = 0.0074; GLI3 mRNA low, 43.1% vs. high, 13.3%, P = 0.0062) and
stage III-IV (5-year overall survival rates: GLI1 mRNA low, 34.0% vs. high, 0%, P = 0.0012; GLI3 mRNA low, 33.4% vs. high,
7.7%, P = 0.057) lung adenocarcinoma patients. GLI2 mRNA expression did not appear to have great clinical significance.
Multivariate analysis revealed higher GLI1 mRNA expression as an independent factor for unfavorable patient survival
(P = 0.0030, hazard ratio = 3.1, 95% confidence interval = 1.5-6.2), as well as tumor differentiation and stage.
Conclusions: Expression of GLI1 and GLI3 mRNA was strongly correlated, and their overexpression, especially that of
GLI1, was found to be predictive of aggressive tumor behavior. This study indicates that the Hh pathway may be a key
oncogenic signaling network in tumor pathogenesis and, thus, a potential therapeutic target in advanced lung
adenocarcinoma.
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Non-small cell lung cancer (NSCLC) has been the leading
cause of cancer-related deaths world-wide, and adenocar-
cinoma accounts for the majority of all NSCLC cases
[1,2]. Although any possibility of a cure rests almost en-
tirely with surgical resection with or without chemo- or
radiotherapy, postoperative recurrence rate is still high
and survival rate remains low compared with other types
of cancers. In particular, advanced NSCLC can be* Correspondence: mishi@kuhp.kyoto-u.ac.jp
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reproduction in any medium, provided the orexceptionally lethal even with aggressive anticancer ther-
apies, despite the dramatic treatment shift of some tar-
geted therapeutic agents for lung adenocarcinoma [3,4].
Developing and deploying new treatment approaches are
vital to improve patient prognoses.
The hedgehog (Hh) signaling pathway, which consists
of three distinct homologues (sonic, indian, and desert Hh)
is constitutively activated in a variety of human tumor en-
tities [5]. Normally, Hh signaling plays an important role
during vertebral embryonic development and tissue main-
tenance [6]. The Hh proteins are secreted molecules, and
their receptor, Patched, usually functions as a downstreaml Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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through binding to the Patched receptor, which unleashes
the transmembrane protein, Smoothened, and ultimately
upregulates GLI [5]. GLI proteins are zinc finger tran-
scription factors which exert their functions by nuclear
localization and promoting target gene transcription, and
in humans, at least three distinct GLI genes, GLI1, GLI2,
and GLI3, have been identified [7]. As the GLI family of
proteins are the final mediators of Hh signaling, their ex-
pression, especially that of GLI1, is deemed to be the best
reflection of the net effect of Hh activation, thus, survival
studies on GLI may indicate the potential involvement of
Hh in tumor pathogenesis [8].
In addition to the tumorigenesis based on genetic alter-
ations of the Hh pathway predominantly seen in basal cell
carcinoma and medulloblastoma, extensive involvement
of ligand-dependent Hh activation has been suggested in
various cancer entities [9,10]. With regard to lung cancer,
while the involvement of Hh signaling in small cell lung
cancer has been shown to be evident [11-13], it remains
poorly understood in lung adenocarcinoma, especially in
the advanced stages.
In this study, we evaluated the expression levels of the
three GLI family genes (GLI1, GLI2, and GLI3) in surgical
samples from advanced lung adenocarcinoma patients
(stage II-IV), and revealed the possible involvement of the
Hh signaling pathway in tumor advancement by analysis
for correlations between GLI expression and patient prog-
nosis. As we found considerable impact of GLI1 and GLI3
gene expression on patient survival, this study demon-
strates that inhibition of Hh signaling may be a promis-
ing drug target for the treatment of advanced lung
adenocarcinoma.
Methods
Patients, tissue samples, and tumor information
Tissue samples were obtained from patients who were
diagnosed as stage II-IV lung adenocarcinoma after sur-
gical resection at the Kyoto University Hospital between
July 2001 and December 2007. Continuous surgical cases
with sufficient tissue material for evaluations were included
in this study (n = 102). All of these tumors were histologi-
cally confirmed as lung adenocarcinoma, and their tumor
staging and degree of differentiation were all assessed
by board-certified pathologists in the Department of
Pathology of the Kyoto University Hospital. Tumor stage
was determined by the latest tumor-node-metastasis clas-
sification system [14]. Histological type and grade of cell
differentiation were determined according to the WHO
classification system [15]. Their demographics and base-
line characteristics are presented in Table 1. Pre- or post-
operative chemotherapy was mainly composed of orally
administered tegafur-uracil and/or conventional intra-
venous chemotherapeutic agents (carboplatin, paclitaxel,docetaxel, gemcitabine, vinorelbine) for NSCLC. Only one
patient (stage II) received radiotherapy prior to surgery
(concurrently with chemotherapy), and postoperative
radiotherapy (mediastinum or chest wall) was performed
in four patients (stage III). Complete tumor resection was
achieved in 77 patients (75.5%), whereas in 25 patients
(24.5%) macro- or microscopic residual tumors were sus-
pected after surgery (for example, pleural dissemination,
malignant pleural effusion, positive stumps, or distant me-
tastasis prior to surgery). Informed consent for participa-
tion in this study was obtained from all patients prior to
their surgeries, and this study was reviewed and approved
by the Ethics Committee of the Graduate School and
Faculty of Medicine at the Kyoto University.
Preparation of tissue mRNA
For sample collection, tumor tissue samples were dis-
sected immediately after surgical resection and soaked in
RNAlater TissueProtect Tubes (Qiagen, Tokyo, Japan) for
more than 48 h before storage at -80°C until use. Total
RNA was isolated from tissue samples using RNeasy Plus
Mini Kit (Qiagen), and reverse transcription of total RNA
was conducted using the Ready-To-Go You-Prime First-
Strand Beads (Amersham Biosciences, Uppsala, Sweden)
to obtain cDNA.
Quantification of GLI mRNA
To quantify GLI mRNA expression levels of each sam-
ple, quantitative real-time PCR was performed using the
LightCycler thermal cycler system (Roche Diagnostics
Japan, Tokyo, Japan). The PCR primers used for the
quantitative amplification of GLI1 mRNA were forward:
5′- CTCCCGAAGGACAGGTATGTAAC -3′ and reverse:
5′- CCCTACTCTTTAGGCACTAGAGTTG -3′, those of
GLI2 mRNA were forward: 5′- AGAAGCAGCGCAAT
GACGTG -3′ and reverse: 5′- GTCATCCAGTGCCGT
CAGGT -3′, and those of GLI3 mRNA were forward: 5′-
AAACCCCAATCATGGACTCAAC -3′ and reverse: 5′-
TACGTGCTCCATCCATTTGGT-3′. The primers for
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mRNA, used as an internal control, were forward:
5′-ACAACAGCCTCAAGATCATCAG-3′ and reverse:
5′-TCTTCTGGGTGGCAGTGATG-3′. After a 20-μL
reaction mixture containing 0.5 μM forward/reverse
primers and 0.03 μg cDNA in QuantiTect SYBR Green
PCR Master Mix (Qiagen) was prepared, PCR amplifica-
tion was initiated by preincubation for 15 min at 95°C for
initial activation, followed by 40 cycles of the following
protocol: denaturation at 94°C for 15 s, annealing at 59°C
for 15 s, and elongation at 72°C for 15 s with detection of
fluorescence products. The quantitative data were ana-
lyzed with LightCycler analysis software version 5.03
(Roche Diagnostics Japan). The expression levels of GLI
genes were calculated as the ratio of GLI mRNA value to
Table 1 Characteristics of the patients included in the study
Numbers (n) Percent (%)
Age (years)





Never smoked 34 33.3
Ex-smoker 20 19.6
Current smoker 48 47.1

























Radiotherapy to thorax (chest wall or mediastinum)a
Yes (Pre/Post) 5 (1/4) 4.9
No 97 95.1
EGFR gene mutation status
Wild-type 46 45.1
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aNot including palliative radiotherapy.
bIncluding residual tumor after surgery.
SD: standard deviation.
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Statistical analysis
Relationships between each pair of mRNA expression
were estimated by calculating the Spearman’s rank cor-
relation coefficient (rs). Pairwise comparisons of postop-
erative survival of each GLI low and high groups were
compared using the Mann-Whitney U test. Survival
curves were evaluated by the Kaplan-Meier method, and
cumulative survival data were compared using the log-
rank test. Multivariate analysis of prognostic factors was
performed by the Cox proportional hazard model. Dif-
ferences were considered significant when P <0.05. All
statistical analyses were performed using StatMate IV
software version 4.01 (ATMS, Tokyo, Japan) and JMP
software version 8 (SAS Institute Japan, Tokyo, Japan).
Results
GLI1, GLI2, and GLI3 mRNA were expressed in almost all
advanced lung adenocarcinoma tissues
GLI1 and GLI3 mRNA expression was detected in all
102 samples, whereas GLI2 mRNA was detected in 99
samples. The level of GLI1 mRNA (normalized and
expressed as a ratio to GAPDH mRNA) ranged from
2.35 × 10-6 to 1.03 × 10-1 (median, 3.03 × 10-4; mean ±
standard deviation, 3.97 × 10-3 ± 1.51 × 10-2); GLI2 mRNA
level was 0 to 1.01 × 10-2 (1.25 × 10-3, 1.78 × 10-3 ± 1.86 ×
10-3); and GLI3 mRNA level was 7.68 × 10-5 to 2.42 × 10-1
(1.07 × 10-2, 2.23 × 10-2 ± 3.93 × 10-2). The three GLImRNA
expression levels in all tissue samples are shown in Figure 1.
Wide variations were observed in GLI1 and GLI3 mRNA
levels in the primary tumor cohort, and based on these,
we defined the upper 15% of patients as high GLI mRNA
expression for each GLI gene (cutoff line; GLI1 mRNA:
2.49 × 10-3, GLI2 mRNA: 3.71 × 10-3, GLI3 mRNA: 3.46 ×
10-2).
GLI1 and GLI3 mRNA expression levels were remarkably
correlated
By comparing GLI1, GLI2, and GLI3 mRNA expression
levels, strong positive correlation was observed between
GLI1 and GLI3 mRNA expression (rs = 0.46, P <0.001)
(Figure 2), whereas no such relations were found be-
tween GLI2 and GLI1 or GLI3 mRNA expression levels.
Even with exclusion of the four observed outliers (n =98), strong positive correlation was also found between
GLI1 and GLI3 mRNA expression (rs = 0.40, P <0.001).GLI1 and GLI3 mRNA expression reflected postoperative
patient survival
There were statistically significant differences in postop-
erative survival between GLI1/GLI3 low and high mRNA
expression groups (GLI1 mRNA: P <0.001; GLI3 mRNA:
P <0.001). Survival curves for each high/low GLI mRNA
expression groups are presented in Figure 3. Five-year
overall survival (OAS) rates in the GLI1 mRNA low and
high groups were 41.7% and 20.0%, and those in the
GLI3 mRNA low and high groups were 43.1% and
13.3%, respectively. Higher GLI1 and GLI3 mRNA ex-
pressing tumors in advanced lung adenocarcinoma pa-
tients were correlated with significantly worse overall
survival rates than lower expression groups (GLI1
mRNA: P = 0.0074, hazard ratio (HR) = 2.2 (95% confi-
dence interval: 1.4-6.9); GLI3 mRNA: P = 0.0062, HR =
2.2 (1.4-6.6)). Similarly, 5-year disease-free survival
(DFS) rates in the GLI1 mRNA low and high groups
were 22.9% and 7.5% (P = 0.086; HR = 1.7 (0.91-3.9)),
and those in the GLI3 mRNA low and high groups were
23.2% and 6.7% (P = 0.0027; HR = 2.3 (1.5-7.1)), respect-
ively. With regard to GLI2 mRNA expression, no statis-
tical significance was observed between high and low
expression groups (OAS: P = 0.32; DFS: P = 0.93).Higher GLI1 mRNA expression was correlated with
significantly worse prognosis especially in stage III-IV lung
adenocarcinoma patients
Subset analysis of patients with stage III-IV lung adeno-
carcinoma (n = 71) showed significantly worse clinical
outcomes in both the higher GLI1 and GLI3 mRNA ex-
pression groups. In this cohort, 5-year OAS rates in the
GLI1 mRNA low and high groups were 34.0% and 0%,
respectively (P = 0.0012, HR = 2.8 (1.9-13.5)), and 5-year
DFS rates in these groups were 18.3% and 0%, respect-
ively (P = 0.027, HR = 2.1 (1.1-7.2)). Although the differ-
ence in OAS between the GLI3 mRNA expression
groups was marginal (low, 33.4% vs. high, 7.7%, P =
0.057), 5-year DFS rates were statistically different be-
tween GLI3 mRNA low and high groups (low, 17.6% vs.
high, 7.7%, P = 0.030, HR = 1.9 (1.1-5.3)). Survival curves
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Figure 1 GLI mRNA expression in stage II-IV lung adenocarcinoma patients. The levels of GLI1, GLI2, and GLI3 mRNA expression were
measured by quantitative real-time polymerase chain reaction in stage II-IV lung adenocarcinoma samples. The three GLI mRNA were detected in
all 102 samples, except three patients who were negative for GLI2. Wide variations were observed in GLI1 and GLI3 mRNA levels. The top 15% of
patients with the highest GLI expression were defined as the higher expression group in each category. Each mRNA value was expressed as a
ratio to GAPDH mRNA (internal control).
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prognostic factor in advanced lung adenocarcinoma
The results of multivariate analyses for each clinicopatho-
logical parameter are presented in Table 2. Higher GLI1
mRNA expression was demonstrated to be an independent
prognostic factor for poor patient prognosis (P = 0.0030,
HR = 3.1 (1.5-6.2)) as well as tumor differentiation (well vs.
poor) and tumor stage. No correlations were found for
GLI2 and GLI3 mRNA expression with other clinicopatho-
logical features.
Discussion
Previous reports on Hh molecules have already provided
us with convincing information on its etiologic contribu-
tion to NSCLC [16]. A large percentage of primary NSCLC
cell lines have been shown to express Hh target genes
including GLI1, indicating constitutive activation of the
Hh pathway in NSCLC cell lines [17]. It was recently
shown that disrupting the Hh pathway inhibited NSCLCproliferation in vitro and abrogated tumor growth in vivo
[18]. In clinical samples, immunohistochemical analysis of
tissue microarray have revealed significant correlation
among the Hh molecules in early-stage NSCLC and of
lymph node metastasis with nuclear GLI1 immunolocal-
ization in lung adenocarcinoma [19,20]. However, the im-
pact of Hh signaling on patient survival has not been
previously reported in NSCLC.
In this study, expression of the three GLI genes was
demonstrated in almost all cases in this cohort, although
their expression levels varied widely. Interestingly, some
lung adenocarcinoma samples showed relatively high
GLI1 and GLI3 mRNA expression, and their expression
patterns were considerably correlated. Although GLI1 is
considered to be the major effector in Hh signaling, the
role of GLI3 is still controversial. Whereas GLI3 acts
mainly as a repressor in normal Hh signaling [21], some
reports have suggested its activator capacity in oncogen-
esis [22-23]. The present study also provides evidence of
Low (n = 87)
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Figure 3 Survival curves according to GLI mRNA expression in stage II-IV lung adenocarcinoma patients. Kaplan-Meier analysis was
performed on the basis of GLI mRNA expression in all cohorts (n = 102). P values were estimated by log-rank test. Tumors with higher expression
(upper 15%) of GLI1 or GLI3 mRNA were associated with poor survival in patients with stage II-IV lung adenocarcinoma. No statistical significance
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Figure 2 Relationship between GLI1 and GLI3 mRNA expression in stage II-IV lung adenocarcinoma patients. Pairwise comparisons of
each GLI mRNA expression level showed that there was a strong positive correlation between GLI1 and GLI3 mRNA expression (rs = 0.46, P
<0.001). Statistical significance was estimated by calculating the Spearman’s rank correlation coefficient (rs). Each mRNA value was expressed as a
ratio to GAPDH mRNA (internal control). Bold value: statistically significant.
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Figure 4 Survival curves according to GLI1 and GLI3 mRNA expression in stage III-IV lung adenocarcinoma patients. Kaplan-Meier
analysis was performed on the basis of GLI1 and GLI3 mRNA expression in patients with stage III-IV lung adenocarcinoma. P values were
estimated by log-rank test. Higher GLI1 and GLI3 mRNA expression also correlated with unfavorable patient survival. (a) Overall survival;
(b) Disease-free survival. Ticks: censored cases; Bold values: statistically significant.
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with GLI1 in advanced lung adenocarcinoma. With re-
gard to GLI2, very little is characterized about its expres-
sion in NSCLC, and only correlation between nuclear
GLI2 with sonic Hh expression in lung squamous cell
carcinoma has been reported [19]. From our research,
no relation between GLI2 mRNA expression and GLI1
mRNA level, GLI3 mRNA level, or patient survival was
detected, thus, the role of GLI2 in the pathogenesis of
lung adenocarcinoma is still unclear.
While GLI1 is mainly regulated at the transcriptional
level, GLI2 is considered as a latent transcriptional regula-
tor that can be activated by Hh signaling. Modification of
the N-terminus of GLI2 is a critical step in the regulation
of the transcriptional activity of the protein [8]. This as well
as the difference in cancer types may explain the discrep-
ancies in GLI2 expression and patient outcomes between
our results and previous ones [24]. Our research is based
on the genetic expression of GLI, whereas for GLI2, it may
be necessary to assess its functional protein level instead.The mechanisms by which Hh signaling is involved in
cancer pathogenesis are not uniform, and there are several
different models of Hh signal transduction. Besides the
most evident pattern of ligand-independent mutational Hh
activation seen in basal cell carcinoma and medulloblas-
toma, ligand-dependent autocrine Hh activation in tumor
cells has also been shown to be common in many cancers
including NSCLC. In addition, ligand-dependent paracrine
Hh signaling that involves the tumor microenvironment
can lead to tumor development [25]. Crosstalk with other
developmental cascades such as Wnt or Notch is also fre-
quently observed [26]. This diversity of Hh signaling in
cancer development in part explains the differences across
cancer types [27,28].
Previous reports on expression profiles of Hh-related
molecules in NSCLC specimens had focused mainly on
the estimation of protein levels by immunohistochemis-
try [19,20], and their gene expression has not been thor-
oughly investigated. This study is unique in that
thorough investigation was performed for the gene
Table 2 Multivariate analysis of GLI1 mRNA expression and other clinicopathological variables for patient survival
Variables Multivariate analysis











Never smoked 1 0.69
Smoker (ex or current) 1.2 0.48-3.1
Tumor differentiation
Well 1
Moderately 1.7 0.83-3.6 0.16
Poorly 2.5 1.1-5.8 0.030
Tumor stage
II 1
III 2.5 1.5-4.5 <0.001
IV 4.2 1.7-9.8 0.0027
EGFR gene mutation status
Wild-type 1
Mutation (+) 1.1 0.58-2.0 0.77
Pre/postoperative chemo- and/or radiotherapy
No 1
Yes 0.67 0.33-1.4 0.29
*Cox’s proportional hazard model.
CI: confidence interval.
Bold values are statistically significant.
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us to directly compare their levels in clinical samples and
to reveal the unexpected correlation between GLI1 and
GLI3 mRNA expression. Interestingly, some GLI1/GLI3
highly expressing tumors (in this cohort, defined as the
upper 15th percentile of patients for each mRNA expres-
sion) showed significantly poorer patient prognosis in ad-
vanced lung adenocarcinoma. Although a statistically
significant negative correlation between survival and GLI1
expression has been shown in breast [29], esophageal [30],
colorectal [31], and bladder cancers [32], this is the first
study to demonstrate a clinical impact of GLI1 on patient
survival in lung adenocarcinoma. Our speculation was fur-
ther supported by the multivariate analysis, which showed
that GLI1 mRNA expression is an indicator for unfavor-
able prognosis. Although the independency of Hh mol-
ecule expression on patient survival has been previouslyshown in bladder and prostate cancers [32,33], we are the
first to reveal that of GLI1 in lung adenocarcinoma, which
is indicative of the involvement of Hh signaling in a subset
of NSCLC. Investigation on GLI3 expression in tumor
samples has been rare, and the possible clinical impact of
GLI3 expression raised by our study needs further corrob-
oration by additional research studies.
Irrespective of these novel observations, some limita-
tions should be addressed in the present study. First, the
validity of the cutoff of mRNA values was not ensured.
Unfortunately, for our data, dichotomizing patients by
either median or mean value of mRNA expression pro-
vided little information on survival difference, thus, we
defined the upper 15% expression level as the cutoff.
Further, patient backgrounds were diverse. Due to the
retrospective nature of analysis of these advanced stage
cancer cases, pre- or postoperative therapies were not
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fully warranted (for example, in stage IV patients, opera-
tions were mainly performed for salvage or diagnosis).
We believe that these limitations can be overcome by
expanding patient numbers and/or careful selection of
patients with similar clinical backgrounds. Additionally,
analyzing the expression profiles of GLI proteins as well
as that of other Hh molecules in this cohort would fur-
ther facilitate the deepening of our understanding.
With the advent of small molecule Hh inhibitors, such
as vismodegib [34,35], recent interest has focused on the
clinical application of Hh inhibitors in various types of tu-
mors harboring aberrantly activated Hh signaling [25,36].
Based on our results, Hh inhibition may be a good candi-
date treatment for advanced lung adenocarcinoma. Be-
cause a similar study on stage I-II lung adenocarcinoma
did not show any significance on patient survival [19], this
signaling pathway may be involved more in tumor pro-
gression rather than tumorigenesis, and disrupting Hh
may be more efficacious in the advanced stages of lung
adenocarcinoma. Further studies including analysis of the
expression of other Hh molecules or on other histological
types of NSCLC are necessary to provide extended sup-
port of our findings.
Conclusions
We found that GLI1, GLI2, and GLI3 mRNA were expressed
in almost all advanced stage lung adenocarcinoma tissue
samples, and strong correlation was observed between
GLI1 and GLI3 mRNA expression. While GLI2 mRNA ex-
pression level was of little clinical significance, a subset of
patients showing relatively high GLI1/GLI3 expression
showed poorer patient survival. In particular, higher GLI1
mRNA expression was an independent prognostic factor
for unfavorable prognosis. This is the first report to de-
scribe the clinical involvement of the GLI family of genes
in advanced lung adenocarcinoma, and these results sug-
gest that Hh signal inhibition is a good candidate thera-
peutic target for advanced stage lung adenocarcinoma,
which provide an impetus for further investigations on the
Hh signaling in NSCLC.
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